溃疡性结肠炎中医综合治疗方案疗效评价研究
|
摘要
1研究目的
以溃疡性结肠炎(UC)慢性复发型和慢性持续型患者为研究对象,采用多中心、随机、平行对照临床试验设计,以传统西药柳氮磺胺吡啶为对照,探讨中医综合治疗方案对溃疡性结肠炎的临床疗效、患者生活质量、用药安全性的影响并进行评价,明确其有效性和安全性,建立优化的溃疡性结肠炎中医规范化治疗方案。
2研究方法
本课题依据相关标准,进行严格的临床研究设计,结合具体临床实际,采用随机、阳性对照的方法,以东直门医院、中日友好医院和首都医科大学附属复兴医院的门诊和住院患者为研究对象,选择溃疡性结肠炎慢性复发型和慢性持续型病例60例。中药组采用中医综合治疗方案分期、分部位治疗,将其分为活动期、恢复期、缓解期进行辨证治疗,分别给予溃结Ⅰ、Ⅱ、Ⅲ号方,并结合不同病变部位给予栓剂或保留灌肠治疗。西药组活动期给予柳氮磺胺吡啶(SASP)每日4-6g,分4次口服；缓解期改为每日1-3g维持缓解巩固治疗；病变部位在直、乙结肠者用柳氮磺胺吡啶栓剂0.5-1g,2次／日。疗程均为3个月,对有效病例随访6个月,主要观察临床综合疗效、中医证候疗效、临床主要症状变化、内镜黏膜疗效、黏膜病理疗效、临床活动指数和内镜指数、血小板计数、复发率及生活质量量表评分的变化,以及安全性指标检测。
3研究结果
3.1临床近期疗效
经过3月的治疗后,经统计学分析,在临床综合疗效、中医证候疗效、内镜黏膜疗效和黏膜病理疗效以及内镜指数方面,中药组和对照组均较治疗前有明显改善(P<0.05),而中药组疗效均优于对照组(P<0.05)。可见,两组治疗UC的临床近期疗效均较满意,中药组疗效更著。
3.2临床远期疗效
治疗3个月后,对经治疗完全缓解及有效的患者(中药组28例,对照组20例)进行了随访,调查治疗后6个月内的复发情况,发现中药组在6个月后随访时的复发率低于对照组,两者存在非常显著性差异(P<0.01)。
动态观察治疗2周、4周、3月后及随访6月的证候积分,可以看出两组均能有效地改善临床症状,其中中药组疗效优于对照组(P<0.05)。从起效的时间段来看,两组在治疗2周后效果相当,无显著差异；从治疗4周后中药组疗效开始优于对照组,治疗3月后疗效优势则更加明显；治疗后6月随访结果显示,中药组疗效较稳定,而对照组积分回升,症状反弹。
而在临床活动指数、血小板计数、大便潜血和大便红细胞计数以及生活质量量表评分方面,治疗3月后中药组和对照组均较治疗前有明显改善(P<0.05),中药组疗效更优于对照组(P<0.05)。治疗后6个月随访,中药组较治疗后变化不明显,而对照组则均有明显改变,两组比较具有显著性差异,P<0.05。
以上结果说明,中药组在远期疗效和抗复发方面更显优势。
3.3安全性疗效
两组不良反应比较,在3个月的治疗过程中,中药组无1例出现不良反应,而对照组则有8例出现不良反应,其不良反应率为27.59%。
在血常规方面,中药组治疗前后红细胞、血红蛋白、白细胞计数无统计学差别,治疗后中药组与对照组比较亦无明显差异。对照组白细胞计数治疗后明显低于治疗前,白细胞有下降的趋势。
尿常规方面,中药组治疗前后尿常规阳性率统计无明显差别,对照组治疗后尿常规阳性率高于治疗前,具有统计学意义,P<0.05。
肝肾功能方面,中药组治疗前后均无明显变化,对照组治疗后肝功能指标ALT和AST均高于治疗前,具有统计学意义,P<0.05。
心电图方面,中药组治疗后心电图阳性率明显低于治疗前,对照组治疗前后心电图变化无明显差别。治疗后中药组与对照组比较具有显著性差异,P<0.01,对照组心电图阳性率增多。
由此看出,中药组在临床长期用药方面更具安全性,对照组则在粒细胞、尿常规、肝功能和心电图等方面可引起不同程度的不良反应。
4结论
以中医辨证论治和西医临床分期相结合、整体脏腑辨证论治与局部用药相结合的中医综合治疗方案治疗溃疡性结肠炎取得了令人满意的临床综合疗效。本方案有效地阻抑了愈后复发,其中在提高完全缓解率及有效率、改善中医证候积分、临床活动指数、内镜指数方面作用皆优于后者,且未出现明显的毒副作用。而中药组的低复发率、低不良反应率都表明本方案能有效阻抑慢性复发型活动期及慢性持续型UC患者愈后复发。因此,本中医综合和治疗方案在临床近期疗效、远期疗效和安全性疗效方面,均明显优于西药柳氮磺胺吡啶,尤其是在改善UC患者生活质量和抗复发方面更显示出其强大的优势,从而为UC中医规范化治疗方案的建立和优化提供可靠的依据。
1 Background and Objective
We took chronic recurrent and chronic resistant type Ulcerative Colitis (UC) as the object of the study. The study adopted multi-center, random, parallel experimental design compared with Sulfasalazine (SASP). We deeply investigated the mechanism of Chinese Medicine in treating from the aspects of clinical general therapeutic effect, patients'living quality, the safety of medicine. We deeply analyzed its effect and safety in order to offer better standardized TCM method in UC treating
2 Methods
The study was strictly designed under the relative guidance. In combination with actual clinical situation, adopting random positive control method.60 cases of chronic recurrent type and chronic resistant type were selected from out patient clinic (OPD) and ward of DongZhimen Hospital, China Japan Friendship Hospital and Fu Xing Hospital attached to Capital Medicine University. The TCM group adopted general plan, treating by stages and positions. We separated patients as active period, convalescence, relieved period so as to diagnose and treated based on overall analysis of the illness and patents'condition. We giveⅠ,Ⅱ,Ⅲulcer prescription respectively with different suppositories in different position or remaining an enema. The active period group in Western Medicine received Sulfalazine (SASP), (4-6g/d) and took 4 times a day. The relieved period group received Sulfalazine(1-3g/d) to consolidate treatment. Illness position in rectum and B colo received SASP (0.5-1g/d).Both treatment course was 3 months and attended 6 months, main observed: Clinical genera effect, therapeutic effect of mucous membrane under endoscopes, therapeutic effect of mucous member, pathology mucous, the change of clinical activity index, the count of blood platelet, the relapse rate and safety index.
3 Results
3.1 Clinical recent curative effect
After three months of treatment, the analysis of statistic show that the treated group and control group all have significant improvement (P<0.01).In the aspect of clinical general therapeutic effect, the TCM syndrome, therapeutic effect of mucous membrane under endoscope, the therapeutic effect of pathology mucous and endoscope index. Treated group is better than control group on all level. As we see, two groups all have satisfied clinical therapeutic effect, and the treated group had better effect.
3.2 Clinical forward curative effects
After curing 3 months, we took random visit to the patients who totally relieved after the treatment (28 cases in treated group,20 cases in control group) in order to investigate relapse situation in six month after treatment. We found the relapse rate in six months of treated group is obviously lower than that of control group (p<0.01)
We observe the Symptom integral of 2weeks,4 weeks and 3months dynamically. We can see that two groups can improve clinical therapeutic effect and treated group hand better treatment than control group (p<0.05). From the time came into effect, two groups had same effect after 2 weeks'treatment and had no significant difference. After 4weeks of treatment, treated group come to being superior with control group. After 3 months the superiority is more significant. The random visit after treatment show that the treated group had stable therapeutic effect, but the integral of control group rise up again and the symptom bound. Therefore we can see that the treated group is safer in the long term. In the aspect of the change of clinical activity index, the count of platelet, Fecal occult blood, Fecal red blood cell count and the living qualities appraisal, treated group and control group all have significant improvement after 3 months'treatment (p<0.05). Treated group had better therapeutic effect than control group (p<0.05).The relapse rate in 6 months of treated group is obviously lower than that of control group. Comparing two groups, there are significant different (p<0.05).
The result above reflects that treated group has more advantage in therapeutic effect and resisting relapse in the long term.
3.3 Security curative effects
During 3 months of treatment, there was no obvious ill-effect on treated group, but 8cases of control group had ill-effect. The rate of ill-effect is 27.95%. In the aspect of blood, there were no statistic differences in RBC, Hemogolbin, and White blood cell count in treated group. Whit blood cell count decreased significantly after treatment in control group. The White blood cell had decreasing trends.
In the aspect of Vrine, there were no significant different in vrine positive statistic rate in treated group after treatment. The vrine positive statistic rate in control group was higher than before. It has sense in statistic (p<0.05).
In the aspect of ECG, ECG positive rate was much lower than before in treated group. There was no difference in control group. A remarkably different can be seen compared with them (p<0.01). The ECG positive rate in control group was increasing.
Therefore, we can conclude that the treated group is safer in long term. It has caused different degrees of ill-effect in Granulocyte, Liver function and CEG in control group.
4 Conclusions
We have got satisfied therapeutic effect in treating UC by using the method of determination of treatment based on differentiation of syndromes, curing by stages and phased delivery. This method resists the relapse effectively. Especially in the ratio of relived, the ratio of effecting, the change of TCM syndrome, endoscope index, clinical activity index compared with Western Medicine. It had no obvious effect either. The low ratio of relapse and ill-effect all reflects that this method can restrain the relapse of chronic recurrent type and chronic resistant type. Therefore, the general TCM method shows its superiority in near and distant therapeutic effect, and safety of the treatment.Especially in the betterment of living quality and restraining of relapse. It proves reliable basis in contributing better standardized TCM pan in UC.
以溃疡性结肠炎(UC)慢性复发型和慢性持续型患者为研究对象,采用多中心、随机、平行对照临床试验设计,以传统西药柳氮磺胺吡啶为对照,探讨中医综合治疗方案对溃疡性结肠炎的临床疗效、患者生活质量、用药安全性的影响并进行评价,明确其有效性和安全性,建立优化的溃疡性结肠炎中医规范化治疗方案。
2研究方法
本课题依据相关标准,进行严格的临床研究设计,结合具体临床实际,采用随机、阳性对照的方法,以东直门医院、中日友好医院和首都医科大学附属复兴医院的门诊和住院患者为研究对象,选择溃疡性结肠炎慢性复发型和慢性持续型病例60例。中药组采用中医综合治疗方案分期、分部位治疗,将其分为活动期、恢复期、缓解期进行辨证治疗,分别给予溃结Ⅰ、Ⅱ、Ⅲ号方,并结合不同病变部位给予栓剂或保留灌肠治疗。西药组活动期给予柳氮磺胺吡啶(SASP)每日4-6g,分4次口服；缓解期改为每日1-3g维持缓解巩固治疗；病变部位在直、乙结肠者用柳氮磺胺吡啶栓剂0.5-1g,2次／日。疗程均为3个月,对有效病例随访6个月,主要观察临床综合疗效、中医证候疗效、临床主要症状变化、内镜黏膜疗效、黏膜病理疗效、临床活动指数和内镜指数、血小板计数、复发率及生活质量量表评分的变化,以及安全性指标检测。
3研究结果
3.1临床近期疗效
经过3月的治疗后,经统计学分析,在临床综合疗效、中医证候疗效、内镜黏膜疗效和黏膜病理疗效以及内镜指数方面,中药组和对照组均较治疗前有明显改善(P<0.05),而中药组疗效均优于对照组(P<0.05)。可见,两组治疗UC的临床近期疗效均较满意,中药组疗效更著。
3.2临床远期疗效
治疗3个月后,对经治疗完全缓解及有效的患者(中药组28例,对照组20例)进行了随访,调查治疗后6个月内的复发情况,发现中药组在6个月后随访时的复发率低于对照组,两者存在非常显著性差异(P<0.01)。
动态观察治疗2周、4周、3月后及随访6月的证候积分,可以看出两组均能有效地改善临床症状,其中中药组疗效优于对照组(P<0.05)。从起效的时间段来看,两组在治疗2周后效果相当,无显著差异；从治疗4周后中药组疗效开始优于对照组,治疗3月后疗效优势则更加明显；治疗后6月随访结果显示,中药组疗效较稳定,而对照组积分回升,症状反弹。
而在临床活动指数、血小板计数、大便潜血和大便红细胞计数以及生活质量量表评分方面,治疗3月后中药组和对照组均较治疗前有明显改善(P<0.05),中药组疗效更优于对照组(P<0.05)。治疗后6个月随访,中药组较治疗后变化不明显,而对照组则均有明显改变,两组比较具有显著性差异,P<0.05。
以上结果说明,中药组在远期疗效和抗复发方面更显优势。
3.3安全性疗效
两组不良反应比较,在3个月的治疗过程中,中药组无1例出现不良反应,而对照组则有8例出现不良反应,其不良反应率为27.59%。
在血常规方面,中药组治疗前后红细胞、血红蛋白、白细胞计数无统计学差别,治疗后中药组与对照组比较亦无明显差异。对照组白细胞计数治疗后明显低于治疗前,白细胞有下降的趋势。
尿常规方面,中药组治疗前后尿常规阳性率统计无明显差别,对照组治疗后尿常规阳性率高于治疗前,具有统计学意义,P<0.05。
肝肾功能方面,中药组治疗前后均无明显变化,对照组治疗后肝功能指标ALT和AST均高于治疗前,具有统计学意义,P<0.05。
心电图方面,中药组治疗后心电图阳性率明显低于治疗前,对照组治疗前后心电图变化无明显差别。治疗后中药组与对照组比较具有显著性差异,P<0.01,对照组心电图阳性率增多。
由此看出,中药组在临床长期用药方面更具安全性,对照组则在粒细胞、尿常规、肝功能和心电图等方面可引起不同程度的不良反应。
4结论
以中医辨证论治和西医临床分期相结合、整体脏腑辨证论治与局部用药相结合的中医综合治疗方案治疗溃疡性结肠炎取得了令人满意的临床综合疗效。本方案有效地阻抑了愈后复发,其中在提高完全缓解率及有效率、改善中医证候积分、临床活动指数、内镜指数方面作用皆优于后者,且未出现明显的毒副作用。而中药组的低复发率、低不良反应率都表明本方案能有效阻抑慢性复发型活动期及慢性持续型UC患者愈后复发。因此,本中医综合和治疗方案在临床近期疗效、远期疗效和安全性疗效方面,均明显优于西药柳氮磺胺吡啶,尤其是在改善UC患者生活质量和抗复发方面更显示出其强大的优势,从而为UC中医规范化治疗方案的建立和优化提供可靠的依据。
1 Background and Objective
We took chronic recurrent and chronic resistant type Ulcerative Colitis (UC) as the object of the study. The study adopted multi-center, random, parallel experimental design compared with Sulfasalazine (SASP). We deeply investigated the mechanism of Chinese Medicine in treating from the aspects of clinical general therapeutic effect, patients'living quality, the safety of medicine. We deeply analyzed its effect and safety in order to offer better standardized TCM method in UC treating
2 Methods
The study was strictly designed under the relative guidance. In combination with actual clinical situation, adopting random positive control method.60 cases of chronic recurrent type and chronic resistant type were selected from out patient clinic (OPD) and ward of DongZhimen Hospital, China Japan Friendship Hospital and Fu Xing Hospital attached to Capital Medicine University. The TCM group adopted general plan, treating by stages and positions. We separated patients as active period, convalescence, relieved period so as to diagnose and treated based on overall analysis of the illness and patents'condition. We giveⅠ,Ⅱ,Ⅲulcer prescription respectively with different suppositories in different position or remaining an enema. The active period group in Western Medicine received Sulfalazine (SASP), (4-6g/d) and took 4 times a day. The relieved period group received Sulfalazine(1-3g/d) to consolidate treatment. Illness position in rectum and B colo received SASP (0.5-1g/d).Both treatment course was 3 months and attended 6 months, main observed: Clinical genera effect, therapeutic effect of mucous membrane under endoscopes, therapeutic effect of mucous member, pathology mucous, the change of clinical activity index, the count of blood platelet, the relapse rate and safety index.
3 Results
3.1 Clinical recent curative effect
After three months of treatment, the analysis of statistic show that the treated group and control group all have significant improvement (P<0.01).In the aspect of clinical general therapeutic effect, the TCM syndrome, therapeutic effect of mucous membrane under endoscope, the therapeutic effect of pathology mucous and endoscope index. Treated group is better than control group on all level. As we see, two groups all have satisfied clinical therapeutic effect, and the treated group had better effect.
3.2 Clinical forward curative effects
After curing 3 months, we took random visit to the patients who totally relieved after the treatment (28 cases in treated group,20 cases in control group) in order to investigate relapse situation in six month after treatment. We found the relapse rate in six months of treated group is obviously lower than that of control group (p<0.01)
We observe the Symptom integral of 2weeks,4 weeks and 3months dynamically. We can see that two groups can improve clinical therapeutic effect and treated group hand better treatment than control group (p<0.05). From the time came into effect, two groups had same effect after 2 weeks'treatment and had no significant difference. After 4weeks of treatment, treated group come to being superior with control group. After 3 months the superiority is more significant. The random visit after treatment show that the treated group had stable therapeutic effect, but the integral of control group rise up again and the symptom bound. Therefore we can see that the treated group is safer in the long term. In the aspect of the change of clinical activity index, the count of platelet, Fecal occult blood, Fecal red blood cell count and the living qualities appraisal, treated group and control group all have significant improvement after 3 months'treatment (p<0.05). Treated group had better therapeutic effect than control group (p<0.05).The relapse rate in 6 months of treated group is obviously lower than that of control group. Comparing two groups, there are significant different (p<0.05).
The result above reflects that treated group has more advantage in therapeutic effect and resisting relapse in the long term.
3.3 Security curative effects
During 3 months of treatment, there was no obvious ill-effect on treated group, but 8cases of control group had ill-effect. The rate of ill-effect is 27.95%. In the aspect of blood, there were no statistic differences in RBC, Hemogolbin, and White blood cell count in treated group. Whit blood cell count decreased significantly after treatment in control group. The White blood cell had decreasing trends.
In the aspect of Vrine, there were no significant different in vrine positive statistic rate in treated group after treatment. The vrine positive statistic rate in control group was higher than before. It has sense in statistic (p<0.05).
In the aspect of ECG, ECG positive rate was much lower than before in treated group. There was no difference in control group. A remarkably different can be seen compared with them (p<0.01). The ECG positive rate in control group was increasing.
Therefore, we can conclude that the treated group is safer in long term. It has caused different degrees of ill-effect in Granulocyte, Liver function and CEG in control group.
4 Conclusions
We have got satisfied therapeutic effect in treating UC by using the method of determination of treatment based on differentiation of syndromes, curing by stages and phased delivery. This method resists the relapse effectively. Especially in the ratio of relived, the ratio of effecting, the change of TCM syndrome, endoscope index, clinical activity index compared with Western Medicine. It had no obvious effect either. The low ratio of relapse and ill-effect all reflects that this method can restrain the relapse of chronic recurrent type and chronic resistant type. Therefore, the general TCM method shows its superiority in near and distant therapeutic effect, and safety of the treatment.Especially in the betterment of living quality and restraining of relapse. It proves reliable basis in contributing better standardized TCM pan in UC.
引文
1.田海河,董建华教授治疗溃疡性结肠炎的经验.北京中医学院学报,1991,14(1)：23-24
2.田德禄,田海河,慢性非特异性溃疡性结肠炎中医研究述评.北京中医学院学报,1992,15(3)：45-46
3.危北海,慢性溃疡性结肠炎的中西医结合防治.中西医结合杂志,1993,13(4)：199-202
4.赵育才,任凤兰,王国三治疗慢性非特异性溃疡性结肠炎经验.上海中医药杂志,1993,(6)：6-7
5.罗珊珊,许东云,难治性溃疡性结肠炎的中医辨证论治规律探讨.云南中医中药杂志,2005,26(1)：58-60
6.王新月,田德禄,溃疡性结肠炎的发病机制与中医辨治思路.中华中医药学会内科脾胃病专业委员会第十五次会议论文集.郑州,2003,294-296
7.冯宗清,杨邵波,自拟肠疡宁汤对溃疡性结肠炎结肠镜象的影响.湖南中医学院学报,1997,17 (3)： 31
8.刘端勇,陈爱民,赵海梅,等,从毒探讨活动期溃疡性结肠炎的发病机制.中国中医基础医学杂志,2004,10(4)：251-253
9.孙继芳.黄河医话.北京科学出版社.1994,244-245
10.中国中西医结合学会消化系统疾病委员会,第四届全国学术交流会慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗性标准(试行方案).中国中西医结合杂志,1994,14：239-240
11.吕迎春,宋怀春,王玉新,等,中医辨证治疗慢性溃疡性结肠炎37例.现代中西医结合杂志,2005,14(8)：1047-109
12.张广业,邢继霞,党传玲,辨证论治配合灌肠治疗溃疡性结肠炎67例.新中医,2005,37(2)： 69
13.梁郁贤,等,辨证治疗慢性非特异性溃疡性结肠炎39例.实用医技杂志,2006,13(3)：427-428
14.王立基,溃愈汤治疗溃疡性结肠炎42例.江苏中医药,2006,27(3)：18-19
15.程越明,固本清燥汤治疗溃疡性结肠炎68例——附SASP治疗对照组40例.天津中医学院学报,1999,18(3)：22
16.戚建明,半夏泻心汤加减治疗溃疡性结肠炎45例临床观察.成都中医药大学学报,2000,23(2)：21-22
17.范喜军,王建楼,张秀江,加味连理汤综合治疗慢性UC36例疗效观,2006,24(5)：49-50
18.张冠群,严清,付莉莉,等,健脾理肠饮治疗慢性溃疡性结肠炎35例.上海中医药杂志,2002, (7)：25-26
19.葛秀英,补气愈肠汤治疗溃疡性结肠炎32例.中国中医药科技,2008,15(9)：389-390
20.连建学,刘宏平,刘卫华,活血化瘀中药治疗UC62例.陕西中医,2006,27(1)：47-49
21.王有鹏,朱永军,孙一鸣,等,结肠灵胶囊治疗溃疡性结肠炎临床观察.黑龙江中医药, 2001,(6)：20-22
22.刘建和,罗文辉,胡国恒,等,愈肠汤对溃疡性结肠炎超氧化物歧化酶的影响及疗效观察.湖南中医学院学报,2001,21(4)：50-51
23.何国强,张和平,中医辨证分型后灌肠治疗溃疡性结肠炎.河南医药信息,2002,10(17)：48-49
24.张洪英,张朋飞,中药灌肠治疗慢性溃疡性结肠炎60例观察.实用中医药杂志,2002,18 (10) ： 7
25.孙士然,陈雪清,加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例.时珍国医国药.2006,17(8)：1537-1539
26.吉红燕,云南白药灌肠治疗溃疡性结肠炎32例.吉林中医,2007,16(2)：40
27.梁启明,王惠政,中药保留灌肠治疗溃疡性结肠炎46例.陕西中医,2002年,23(7)：610
28.周秦汉,俞军,谷淑玲,速效溃结散保留灌肠治疗慢性非特异性溃疡性结肠炎临床与实验研究.中国中西医结合杂志,1999,19(7)：395-397
29.卓红曼,等,红藤败毒汤治疗慢性溃疡性结肠炎42例.浙江中医杂志,2007,42(3)：152
30.潘洋,于春光,战晶玉,青白灌肠液治疗溃疡性结肠炎60例临床观察.中国中医药科技,2002,9 (4) ： 220
31.王建生,中药保留灌肠治疗溃疡性结肠炎30例临床观察.淮海医药,2007,25(3)：243-244
32.范慈君, “结肠炎方”灌肠治疗溃疡性结肠炎.现代实用医学,2003,15(7)：24-26
33.沈国梁,中药保留灌肠治疗溃疡性结肠炎41例.云南中医中药杂志2008,27(4)：12
34.邱夏桑,中药治疗慢性溃疡性结肠炎疗效分析.中国中西医结合脾胃杂志,2000,8(4)：248
35.刘丽芳,辨证配合中药保留灌肠治疗溃疡性结肠炎60例临床观察.湖南中医学院学报,2002,22(3)：8-59
36.李啸晨,邓建光,内外合治溃疡性结肠炎54例.湖南中医杂志,2006,22(4)：48
37.刘少琼.四白汤口服加灌肠治疗溃疡性结肠炎60例.陕西中医,2007,28(1)：56-58
38.李虎臣,刘光茂,赵素云,愈疡灵治疗溃疡性结肠炎96例.中国中西医结合消化杂志,2002,10(1)： 17
39.潘爱珍,马齿苋汤治疗溃疡性结肠炎疗效观察.时珍国医国药,2002,13(6)：359
40.候惠芳,饶秦文,肠宁方治疗慢性溃疡性结肠炎58例临床观察.陕西中医学院学报,2000,23(3)： 21
41.李占林,肠溃汤口服兼灌肠治疗溃疡性结肠炎60例.时珍国医国药,2006,17(5)：799-800
42.武玉杰,等,中药口服灌肠并用治疗溃疡性结肠炎150例.实用中医内科杂志,2006,20(3)： 313
43.闫伯君,中西医结合治疗溃疡性结肠炎疗效观察.天津中医学院学报,2000,19(4)： 7
44.吴忠珍,中西医结合治疗非特异性溃疡性结肠炎56例.河南中医学院学报,2005,20(2)：52-53
45.王晓平,乌梅丸加减治疗溃疡性结肠炎28例.中国民间疗法,2002,10(11)：52-53
46.王纪东,中西医结合治疗溃疡性结肠炎初探.河南大学学报(医学科学版),2001,20(9)：85
47.季永海,汤荣兰,金水宝胶囊治疗溃疡性结肠炎59例临床观察.中草药,2000,31(2)：122-123
48.吴丽梅,杨宏玲,于青,中西医结合灌肠治疗慢性溃疡性结肠炎.中医药学报,1999(5)：17
49.杨智海,杨东威,中西医结合治疗慢性溃疡性结肠炎64例.湖北中医杂志,2000,22(11)：5
50.史肃育,中西药治疗慢性溃疡性结肠炎63例疗效分析.时珍国医国药,2000,11(4)：54
51.邱建强,崔晓蔷,张彦,中西医结合治疗溃疡性结肠炎44例.陕西中医,2003,24(7)：27
52.张绪生,乌梅诃子合剂治疗溃疡性结肠炎68例临床疗效观察.中国中药杂志,2002,27(10)：796-797
53.孙启光,张亚春,刘淑芹,等,中西医结合辨证分型治疗慢性非特异性溃疡性结肠炎55例.中国中西医结合杂志,2000,20(12)：946-947
54.李春颖,李素娟,中西医结合治疗溃疡性结肠炎60例疗效观察.河南中医,2002,22(5) ： 77
55.严建,中西医结合治疗慢性溃疡性结肠炎68例.湖南中医药导报2002,8.(6)：323,331
56.何家桐,黄芪建中汤合用柳氮磺吡啶、氢化可的松治疗溃疡性结肠炎疗效观察.广东医学院学报,2002,20(4)：16-18
57.席作武,活血化瘀法治疗溃疡性结肠炎82例.中国中西医结合脾胃杂志,2000,8(3)：161-162
58.金丹,胡江鸿,中西医结合治疗溃疡性结肠炎46例.海南医学,2006,17(1)：100-102
59.邢全台,袁孟彪,康妇消炎栓灌肠治疗溃疡性结肠炎38例观察.中国临床医生,2002,30(7)：28-29
60.林燕,王新月,田德禄,崔巍,李晓林,温下法与温涩法对溃疡性结肠炎外周血T淋巴细胞亚群的影响.中国中西医结合消化杂志,2006,14(2)：78-81
61.郭颂铭,杨巍,中药组方灌肠对实验性溃疡性结肠炎的免疫影响.上海铁道医学院学报,1995,9(4)219-222
62.周玲玲,方泰惠,杨舜民,等,复方苦参胶囊对大鼠免疫性结肠炎的保护作用.陕西中医,2004,25(1)：89-91
63.石云琼,刘少平,针灸治疗对溃疡性结肠炎患者细胞因子的影响.湖北中医杂志,2006,28(2)：11-13
64.丁水平,丁水生,李涵志,算盘子对溃疡性结肠炎大鼠细胞因子的影响.医药导报,2002,21(2)：76-77
65.王新月,杨莉莉,王雪茜,顾立刚,田德禄,溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响.中国中西医结合消化杂志,2006,14(6)：351-354
66.郑红斌,胡鸿毅,陆雄,等,清肠栓对溃疡性结肠炎防治作用的动物实验研究.上海中医药大学学报,2000,14(4)：54-56
67.高文艳,王长洪,林一帆,等,化瘀通络汤对大鼠实验性溃疡性结肠炎血小板活化的影响.中国中西医结合消化杂志,2007，15(2)：81-84
68.赵复锦,张雄,余小平,等,通因通用法治疗溃疡性结肠炎的临床及实验研究.中国中西医结合消化杂志,2005,13(2)：85-87
69.朱炳喜,吕愈敏,叶嗣懋,丹参对大鼠乙酸性溃疡性结肠炎黏膜保护作用的研究.中国中西医结合脾胃杂志,2000,8(4)：214-245
70.郑舜华,崔儒涛,补肺益肠方治疗溃疡性结肠炎的实验研究.上海中医药杂志,2000,(6)：10-12
71.江学良,权启镇,王东,等,鱼腥草治疗溃疡性结肠炎大鼠对结肠压力的影响.世界华人消化杂志,1999,7(7)：639
72.陈治水,危北海,张万岱,李道本,溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005,13(2)：133-136
1. Hanauer SB, Inflammatory bowel disease. In:Bennett JC, Plum F (eds.). Cecil Textbook of Medicine.20th ed Philadelphia:W. B.Saunders Company,1996, 707-715
2. Park SH, Kim YM, Yang SK, Kim SH, Byeon JS,Myung SJ, Cho YK, YuCS, Choi KS, Chung JW, Kim B, Choi KD, Kim JH. Clinical features andnatural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007,13:278-283
3. Br andt LJ, Bo l e y S J, Mi t sudo S, Clinical characteristics and natural history of colitis in theelderly. Am J Gastroenterol,1982,77:382-386
4. Lakatos PL, Recent trends in the epidemiology of inflammatory bowel diseases:up or down? World JGastroenterol,2006,12:6102-6108
5. Lakatos L, Lakatos PL, Is the incidence andprevalence of inflammatory bowel diseasesincreasing in Eastern Europe? Postgrad Med J 2006,82:332-337
6. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J, Colorectal cancer prevention in ulcerative colitis:a case-controlstudy. Aliment Pharmacol Ther.2000,14:145-153
7. Ameho CK, Adje i AA,Harrison EK, et al, Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor a production in trinitrobenzene sulphonic acid induced col it is.Gut,1997, 41(4):487-493
8. Bach MA, Bach JF, The use of monoclonal anti-T cell antibodies to study T cell imbalance in human diseases. Clin Exp Immunol,1981,45:449-456
9. Bhan AK,Mizoguchi E, Smith RN, et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev,1999,169:195-207
10. Neurath MF,Immunotherapy of inflammatory bowel disease:current concepts and future perspectives. Arch Immunol Ther Exp (Warsz),2000,48:81-84
11. Inoue S, Mat sumo to T, IidaM, et al, Characterization of cytokine expression in. the rectal mucosa of ulcerative colitis:correlation with disease activity. Am Jgastroenterol,1999,94:2441-2446
12. Lijima H,Takahashi I, Kishi D, et al, J Exp Med,1999,190(5):607-615
13. Boirivant M,Rennert PD, J Exp Med,1999,189(8):1169-1180
14. Dohi T, Fujihashi K,Kiyono H, et al, Gatroenterology,2000,119(6):724-733
15. Niessner M, Volk BA, Altetred Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Inmmunol,1995Sep,101:428-435
16. Fuss J, Neurath M,Boirivant M,et al, Disparate CD4+ lamina propria(LP) lympokine secretion profiles in inflammatory bowel disase. Crohn's disease Lpcells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest incersed secretion of IL-5.J Immunol,1996, 157:1261-1270.
17. Biuruvabt M, et al, J Exp Med,1998,188 (10):1929-1939
18.Macdlonald.TT, Gut,1998,42 (4):460-461
19. Schreiber S, Experimental immunomodulatory therapy of inflammatorybowel disease. Netherl J Med 1998,53:24-31
20.李琪佳,徐敏,宫恩聪,细胞因子与溃疡性结肠炎.中国煤炭工业医学杂志2001,4：411-413
21.Ferretti M, Neutralization of endogenous IL-lreceptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.J Clin Invest,1994,94:449-453
22.朱峰,钱家鸣,潘国宗,等,白细胞介素1β和白细胞介素8在实验性结肠炎发病中的作用及白细胞介素1受体拮抗剂治疗作用的探讨.中国医学科学院学报,1998,20：388-394
23. Cominelli F,Kam L,Casini-Raggi V,et al, Specific mucosal imbalance of IL-1 and IL-1 receptor antagonit (IL-lra). in IBD:A potential mechanism of chronic infammation. Gastroenterol,1994,106:A667
24..Isaacs KL, Sartor RB, Haskill S, et al, Cytokine messenger RNA profiles in inflammatory bowel disease muosa detected by polymerase chain reaction amplification. Gastroenterol,103:1587-1595,1992
25丁伟群,林庚金,徐三荣,钱立平,溃疡性结肠炎发病中白介素水平的变化.复旦学报2001,7：330-335
26 Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET,Strom TB, Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic of IL-1, IL-6 and TNF-g. J Immunol,1991,146:3523-3527
27 Willems J, Joniau M, Cinque S, van Damme J, Human granulocytechemotactic peptide (IL-8) as a specific neutrophildegranulator:comparison with other monokines. Immunology,1989,67:540-542
28 Mazzucchelli L, Hauser C, Zgraggen K, Wagner H, Hess M,Laissae JA, Mueller C, Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol,1994,144:997-1007
29. Kullberg MC, Ward JM,Gorelick PL,et al, Helicobacter hepatieus Triggers Colitis in Specific-Pathogen-Free Interleukin-10(IL-10)-Deficent Mice through an IL-2 and Gamma Interferon-Dependent Mechanism.Infect Immunol,1998,66:5157-5166
30. Schreiber S,Heinig T,Panzer U,et al, Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology,1995,108:21-23
31. Mullin GE, Vezza FR, Sampat A,et al, Abnormal IL-10 mRNA production in the intestinal mucosal lesions of inflammatory bowel disease. Gastroenterology 1993,104(3),182-188
32. Schreibei S, Heining T, HeiningT, et al, Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology,1995 Jan,108(1):35-66
33 Nielsen OH, Koppen T, Rudiger N, Horn Y, Eriksen J, KirmanL, Involvement of interleukin-4 and 10 in inflammatory boweldisease. Dig Dis Sci,1996,41:1786-1793
34 Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahonR, Whorwell PJ, Sinnott PJ, Hutchinson IV, Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigen,1999,54:386-390
35 Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, ParsonsHG, Madsen KL, Inhibition of poly (ADP-ribose) polymeraseattenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol,2000,279:641-651
36. Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A, Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line:role of the microtubule cytoskeleton. Free Radic Biol Med,2000,28:727-38
37. Oudkerk P, Bouma G,Visser T T, et al, Serumnitrate level in ulcerative colliti and Crohrs disease. Scand J Gastroenterol,1995,30:784-788
38. Grisham MB, Oxidants and free radicals in inflammatory bowel disease. Lancet, 1994,344:859-861
39. Collins CE, Cahill MR, Newland AC, Rampton DS, Platelets circulate in an actived state in inflammatory bowel disease. Gastroenter.ology,1994,106 (4):840-845 40. Nielsen OH,Brynskov J, Vainer B, Dig Dis. Sci,1996,41 (9):1780-1785
41. Koizumi M,King N, Lobb R,et al, Gastroenterology,1992,103 (3):840-847
42. Schumann GM.Bishop AE,Facer P,et al, Gut,1995,36 (7):411-418
43. 费保莹,细胞粘附分子与炎症性肠病.国外医学消化系统疾病分册,1999；19(1)： 15-17
44. Simmonds NJ, AllenRE, Stevens TRJ, et al, Chemilum inescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology,1992, 103:186-192
45. SedghiS, KeshavarzianA, KlamutM, et al, Elevated breath ethane levels inactive ulcerative colitis:Evidence for. excessive lipid peroxdation. Am J Gastroenterol, 1994,89:2217-2221
46.Tannahill CL, Stevenot SA, Campbell-Thompson M, e tal, Induction and immunolocalization of manganese super oxide dismutase in acute acetic acid-induced colitis in the rat. Gastroenterology,1995,109:800-805
47. Mulder TPJ, Verspaget HW, Janssens AR, et a, Decreases in two ntestinal. Cu/Zn containing proteins with an-tioxidant function in inflammatory bowel disease.Gut,1991,32:1146-1150
48. Ueyama H,et al, Gut,1998,43(1):48-55
49. Maciejewski J, Selleri C, Sato T, et al, Br J Haematol,1995/91:245-252
50.Anel A, Buferne M Boyer C, et al, Eur J Immunol,1.994,24(10):2469-2476
51. Callera F, Garcia AB, Falcai RP, et al, Br J Haematol,1998,100:698-703
52.吴国新,阮长耿, 血小板颗粒膜蛋白研究进展.中华血液杂志,1994,15(3)：162
53.江学良, 溃疡性结肠炎患者血小板活化的检测.新消化病杂志,1997,11(5)：736
54. Collins CE, Cihill MR, Newland AC,et al, Platelets circulation in anactivated state in inflammatory bowel disease. Gastroenterology,1994,106(4):840-845
55.徐萍,吴锡琛,血小板功能障碍：炎症性肠病研究的一种新动向.国外医学消化系统疾病分册,1996,16(1)：43
56.Graef V. Baggenstoss AH, Sauer WG, et al, Venous thromblsis occurring in nonspecific ulcerative colitis. Arch Intern Med,1996,117(3):337
57.张连峰,田曙光,王国新,溃疡性结肠炎患者血小板功能状态的研究.中国实用内科杂志,2000,20(2)：98-99
58. Sedghi S, Fields JZ, Klamut M, et al, Increased production of luminal enhanced chem. Hum in escence by the inflamed colonic mucosa in patients with ulcerative colitis.Gut,1993,34:1191-1195
59, Kerr 1F, Wyllle AH, Cntrie AR, Apoptosis:a basic biological phenomenon.with wikl ranging implications in tissue kinctics. Br J C mtar,1972,26:239-245
60. IwamotoM, Koji T,Makiyama K, Kohyski N, Nakane PK, Apoptosis of crypt Epithelial cell in ulcerative colitis. J Pathol 1996,180:152-159
61严瑾,欧阳钦,陈代云,等,溃疡性结肠炎中Fas/FasL介导的结肠上皮细胞凋亡.中华消化杂志,2001,21：397-399.
62张文俊,李兆申,许国铭,等,细胞调亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达的研究.中华消化内镜杂志,2003,20：262-264
63祝斌,李巧勤,陈垦,等,溃疡性结肠炎患者PMM凋亡与细胞因子水平及Bcl-2基因表达的关系.中国肛肠病杂志,2004,24：3-6.
64江学良,权启镇,孙自勤,王要军,齐风,王东,张修礼,‘溃疡性结肠炎患者淋巴细胞凋亡调控蛋白的表达.世界华人消化杂志,1999,7：902-905
65 Neurath M F, Finotto S, FussI, Boirivant M, Galls PR, Strober'W, Regulation of T-cell apoptosis in inflammatory bowel disease:to d ie or not to die, that is the mucosal question. Trends Immunoi 2001,22:21-26
66. Orholm M,Binder V, Sorensen TI, Rasmussen LP, Kyvik KO, Concordance of inflammatory bowel disease among Danish twins:results of a nationwide study. Sand J Gastroenterol,2000,35:1075-1081
67. Orchard TR,Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000,118:274-278
68. Einerhand AW, Renes IB, Makkink MK, Van Der Sluts M Buller HA, Dekker J. Role of mucins in inflammatory bowel disease:important lessons from experimental models. Eur J Gastroenterol Hepatml,2002,14:757-765
69. Birrenbach T, Bocker U, Inflammatory boweldisease and smoking:a review of epidemiology,pathophysiology, and therapeutic implications. Inflamm Bowel Dis,2004, 10:848-859
70. Cosnes J, Tobacco and IBD:relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol,2004,18:481-496
71. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS, Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol,1988,23: 1147-1152
72. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR, Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis, 2007,13:108-115
73. Scott DA, Martin M, Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J Gastroenterol,2006, 12:7451-7459
74. Ingram JR, Rhodes J, Evans BK, Thomas GA, Preliminary observations of oral nicotine therapy for inflammatory bowel disease:an open-label phase Ⅰ-Ⅱ study of tolerance. Inflamm Bowel Dis,2005,11:1092-1096
75. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J, Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy:a pilot study. Aliment Pharmacol Ther,1997,11:663-671
76 Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD, Transdermal nicotine for mildly to moderately active ulcerative colitis. Arandomized, double-blind, placebo-controlled trial. Ann Intern Med,1997,126:364-371
77 Jantchou P, Monnet E, Carbonnel F, Environmental risk factors in Crohn's disease and ulcerative colitis (excluding tobacco and appendicectomy). Gastroenterol Clin Biol,2006,30:859-867
78 Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA, Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005,22:309-315
79 Godet PG, May GR, Suther land LR, Metaanalysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995,37:668-673.
80. Mayer EA, The neurobiology of stress andgastrointestinal disease. Gut,2000, 47:861-8698
81. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, KeM, Tache Y, Wood JD. Fundamentals of neurogastroenterology:basic science. Gastroenterology,2006,130:1391-1411
82 Heinrichs SC, Tache Y, Therapeutic potential ofCRF receptor antagonists:a. gut-brain perspective.Expert Opin Investig Drugs,2001,10:647-659
83. Glavin GB, Murison R, Overmier JB, Pare WP,Bakke HK, HenkePG, Hernandez DE, The neurobiology of stress ulcers. Brain Res Brain Res Rev,1991,16:301-343
84. Madara JL, Podolsky DK, King NW, Sehgal PK, Moore R, Winter HS, Characterization of spontaneous colitis in cottontoptamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology,1985,88(1 Pt 1):13-19
85. Theis MK, Boyko EJ, Patient perceptions of causes of inflammatory bowel disease. Ain J G astroenterol,1994,89:1920
86.Mayer EA, The neurobiology of stress and gastrointestinal disease. Gut,2000, 47:861-869
87.] Qiu BS, Valiance BA, Blennerhassett PA, Collins SM, The role of CD4+lymphocytes in the susceptibility of mice to stress induced
88. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, Gonzalez-Huix F, Rier.a J, Gonzalez-Lara V, Dominguez-Abascal F, Gine JJ,Moles J, Gomollon F, Gassull MA, Randomizedclinical trial of Plantago ovata seeds (dietary fiber)as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol,1999,94:427-433
89. Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH, Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr, J 2005,4:7
90. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR, Influence of dietary factors on the clinical course of ulcerative colitis:a prospective cohort study. Gut,2004,53:1479-1484
91 Tilg H, Kaser A, Diet and relapsing ulcerative colitis:take off the meat? Gut, 2004,53:1399-1401
92 Winawer SJ, Screening of colorectal cancer. Surg Oncol Clin N Am,2005,14:699-722
93 Russel MG, Engels LG, Muris JW, Limonard CB, Volovics A, Brummer RJ, Stockbrugger RW, Modern life'in the epidemiology of inflammatory bowel disease:a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol, 1998,10:243-249
94 Guarner F, Microecology as a target for therapeutic intervention in inflammatory bowel disease. Idrugs,2003,6:868-873
95 Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H, Mucosal flora in inflammatory bowel disease. Gastroenterology,2002,122:44-54
96 Katz JA, Itoh J, Fiocchi C, Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol,1999,15:291-297
97.董军梅,魏琴,柳氮磺吡啶保留灌肠加电磁波治疗溃疡性结肠炎. 中国中医药现代远程教育,2008,6：784
98.吴小珑,陈健芳,柳氮磺胺吡啶等保留灌肠治疗溃疡性结肠炎.基层医学论坛,2006,10： 719-720
99. 严明确,白学松,任文涛,溃疡性结肠炎药物治疗的现状. 现代医药卫生,2006,22： 2817-2818
100. 宋卫生,刘思德,溃疡性结肠炎药物治疗进展.中国消化内镜,2008,2：18-20
101. Jarnerot G, Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology,2006,130:286, author reply 287
102. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ,Present D, Sands BE, Colombel JF, Infliximabfor induct ion and maintenance therapy for ulcerative colitis. N Engl J Med,2005,353:2462-2476
103.何相宜, 陈维雄,英昔单抗治疗中至重度溃疡性结肠炎的研究进展. 国际消化病杂志,2007,27：169-171
104钱家鸣,路新卿,肿瘤坏死因子拮抗剂治疗炎症性肠病. 中国实用内科杂志,2007,27： 1442-1444
105夏冰,程虹,溃疡性结肠炎的生物治疗. 临床消化病杂志,2007,19：1-19
106杨景勋,Infliximab不良反应.药物不良反应杂志,2001,3：176-178
107张道权,吴正祥,炎症性肠病的抗肿瘤坏死因子治疗安全评价. 临床荟萃,2007,22： 145-147
108 Lees CW, Ali A, Thompson AI, Ho GT, ForsytheRO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR,Wilson DC, Arnott ID, Satsangi J, The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice:analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2008 N.ov 4. [Epub ahead of print]
109 Shah SB, Hanauer SB, Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord,2008,8:159-168
110陈尉华,陆伦根,炎症性肠病生物制剂治疗的研究进展.胃肠病学,2007,12：252-254
111庞智,郑家驹,炎症性肠病生物学治疗的研究进展. 中国处方药,2007,6：39-41
112何影,欧阳钦,生长因子治疗炎症性肠病.国际消化病杂志,2007,27：164-166
1.中华医学会消化病学分会炎症性肠病协作组,对我国炎症性肠肠病诊断治疗规范的共识意见.胃肠病学,2007,12(8)：488-494
2.贾黎明,周春立,炎症性肠病的内镜检查.炎症性肠病基础与临床.北京：科学出版社,2001,195
3.施先艳,邓长生.溃疡性结肠炎.炎症性肠病。北京：人民卫生出版社,1998,183
4. Rachmilewitz D, On behalf of an International Study Group. Coated mesalazine (5-aminosallicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis:a randomised trial. Br Med J,1989,298:82-86
5.陈治水,危北海,张万岱,李道本,溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005,13(2)：133-136
2.田德禄,田海河,慢性非特异性溃疡性结肠炎中医研究述评.北京中医学院学报,1992,15(3)：45-46
3.危北海,慢性溃疡性结肠炎的中西医结合防治.中西医结合杂志,1993,13(4)：199-202
4.赵育才,任凤兰,王国三治疗慢性非特异性溃疡性结肠炎经验.上海中医药杂志,1993,(6)：6-7
5.罗珊珊,许东云,难治性溃疡性结肠炎的中医辨证论治规律探讨.云南中医中药杂志,2005,26(1)：58-60
6.王新月,田德禄,溃疡性结肠炎的发病机制与中医辨治思路.中华中医药学会内科脾胃病专业委员会第十五次会议论文集.郑州,2003,294-296
7.冯宗清,杨邵波,自拟肠疡宁汤对溃疡性结肠炎结肠镜象的影响.湖南中医学院学报,1997,17 (3)： 31
8.刘端勇,陈爱民,赵海梅,等,从毒探讨活动期溃疡性结肠炎的发病机制.中国中医基础医学杂志,2004,10(4)：251-253
9.孙继芳.黄河医话.北京科学出版社.1994,244-245
10.中国中西医结合学会消化系统疾病委员会,第四届全国学术交流会慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗性标准(试行方案).中国中西医结合杂志,1994,14：239-240
11.吕迎春,宋怀春,王玉新,等,中医辨证治疗慢性溃疡性结肠炎37例.现代中西医结合杂志,2005,14(8)：1047-109
12.张广业,邢继霞,党传玲,辨证论治配合灌肠治疗溃疡性结肠炎67例.新中医,2005,37(2)： 69
13.梁郁贤,等,辨证治疗慢性非特异性溃疡性结肠炎39例.实用医技杂志,2006,13(3)：427-428
14.王立基,溃愈汤治疗溃疡性结肠炎42例.江苏中医药,2006,27(3)：18-19
15.程越明,固本清燥汤治疗溃疡性结肠炎68例——附SASP治疗对照组40例.天津中医学院学报,1999,18(3)：22
16.戚建明,半夏泻心汤加减治疗溃疡性结肠炎45例临床观察.成都中医药大学学报,2000,23(2)：21-22
17.范喜军,王建楼,张秀江,加味连理汤综合治疗慢性UC36例疗效观,2006,24(5)：49-50
18.张冠群,严清,付莉莉,等,健脾理肠饮治疗慢性溃疡性结肠炎35例.上海中医药杂志,2002, (7)：25-26
19.葛秀英,补气愈肠汤治疗溃疡性结肠炎32例.中国中医药科技,2008,15(9)：389-390
20.连建学,刘宏平,刘卫华,活血化瘀中药治疗UC62例.陕西中医,2006,27(1)：47-49
21.王有鹏,朱永军,孙一鸣,等,结肠灵胶囊治疗溃疡性结肠炎临床观察.黑龙江中医药, 2001,(6)：20-22
22.刘建和,罗文辉,胡国恒,等,愈肠汤对溃疡性结肠炎超氧化物歧化酶的影响及疗效观察.湖南中医学院学报,2001,21(4)：50-51
23.何国强,张和平,中医辨证分型后灌肠治疗溃疡性结肠炎.河南医药信息,2002,10(17)：48-49
24.张洪英,张朋飞,中药灌肠治疗慢性溃疡性结肠炎60例观察.实用中医药杂志,2002,18 (10) ： 7
25.孙士然,陈雪清,加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例.时珍国医国药.2006,17(8)：1537-1539
26.吉红燕,云南白药灌肠治疗溃疡性结肠炎32例.吉林中医,2007,16(2)：40
27.梁启明,王惠政,中药保留灌肠治疗溃疡性结肠炎46例.陕西中医,2002年,23(7)：610
28.周秦汉,俞军,谷淑玲,速效溃结散保留灌肠治疗慢性非特异性溃疡性结肠炎临床与实验研究.中国中西医结合杂志,1999,19(7)：395-397
29.卓红曼,等,红藤败毒汤治疗慢性溃疡性结肠炎42例.浙江中医杂志,2007,42(3)：152
30.潘洋,于春光,战晶玉,青白灌肠液治疗溃疡性结肠炎60例临床观察.中国中医药科技,2002,9 (4) ： 220
31.王建生,中药保留灌肠治疗溃疡性结肠炎30例临床观察.淮海医药,2007,25(3)：243-244
32.范慈君, “结肠炎方”灌肠治疗溃疡性结肠炎.现代实用医学,2003,15(7)：24-26
33.沈国梁,中药保留灌肠治疗溃疡性结肠炎41例.云南中医中药杂志2008,27(4)：12
34.邱夏桑,中药治疗慢性溃疡性结肠炎疗效分析.中国中西医结合脾胃杂志,2000,8(4)：248
35.刘丽芳,辨证配合中药保留灌肠治疗溃疡性结肠炎60例临床观察.湖南中医学院学报,2002,22(3)：8-59
36.李啸晨,邓建光,内外合治溃疡性结肠炎54例.湖南中医杂志,2006,22(4)：48
37.刘少琼.四白汤口服加灌肠治疗溃疡性结肠炎60例.陕西中医,2007,28(1)：56-58
38.李虎臣,刘光茂,赵素云,愈疡灵治疗溃疡性结肠炎96例.中国中西医结合消化杂志,2002,10(1)： 17
39.潘爱珍,马齿苋汤治疗溃疡性结肠炎疗效观察.时珍国医国药,2002,13(6)：359
40.候惠芳,饶秦文,肠宁方治疗慢性溃疡性结肠炎58例临床观察.陕西中医学院学报,2000,23(3)： 21
41.李占林,肠溃汤口服兼灌肠治疗溃疡性结肠炎60例.时珍国医国药,2006,17(5)：799-800
42.武玉杰,等,中药口服灌肠并用治疗溃疡性结肠炎150例.实用中医内科杂志,2006,20(3)： 313
43.闫伯君,中西医结合治疗溃疡性结肠炎疗效观察.天津中医学院学报,2000,19(4)： 7
44.吴忠珍,中西医结合治疗非特异性溃疡性结肠炎56例.河南中医学院学报,2005,20(2)：52-53
45.王晓平,乌梅丸加减治疗溃疡性结肠炎28例.中国民间疗法,2002,10(11)：52-53
46.王纪东,中西医结合治疗溃疡性结肠炎初探.河南大学学报(医学科学版),2001,20(9)：85
47.季永海,汤荣兰,金水宝胶囊治疗溃疡性结肠炎59例临床观察.中草药,2000,31(2)：122-123
48.吴丽梅,杨宏玲,于青,中西医结合灌肠治疗慢性溃疡性结肠炎.中医药学报,1999(5)：17
49.杨智海,杨东威,中西医结合治疗慢性溃疡性结肠炎64例.湖北中医杂志,2000,22(11)：5
50.史肃育,中西药治疗慢性溃疡性结肠炎63例疗效分析.时珍国医国药,2000,11(4)：54
51.邱建强,崔晓蔷,张彦,中西医结合治疗溃疡性结肠炎44例.陕西中医,2003,24(7)：27
52.张绪生,乌梅诃子合剂治疗溃疡性结肠炎68例临床疗效观察.中国中药杂志,2002,27(10)：796-797
53.孙启光,张亚春,刘淑芹,等,中西医结合辨证分型治疗慢性非特异性溃疡性结肠炎55例.中国中西医结合杂志,2000,20(12)：946-947
54.李春颖,李素娟,中西医结合治疗溃疡性结肠炎60例疗效观察.河南中医,2002,22(5) ： 77
55.严建,中西医结合治疗慢性溃疡性结肠炎68例.湖南中医药导报2002,8.(6)：323,331
56.何家桐,黄芪建中汤合用柳氮磺吡啶、氢化可的松治疗溃疡性结肠炎疗效观察.广东医学院学报,2002,20(4)：16-18
57.席作武,活血化瘀法治疗溃疡性结肠炎82例.中国中西医结合脾胃杂志,2000,8(3)：161-162
58.金丹,胡江鸿,中西医结合治疗溃疡性结肠炎46例.海南医学,2006,17(1)：100-102
59.邢全台,袁孟彪,康妇消炎栓灌肠治疗溃疡性结肠炎38例观察.中国临床医生,2002,30(7)：28-29
60.林燕,王新月,田德禄,崔巍,李晓林,温下法与温涩法对溃疡性结肠炎外周血T淋巴细胞亚群的影响.中国中西医结合消化杂志,2006,14(2)：78-81
61.郭颂铭,杨巍,中药组方灌肠对实验性溃疡性结肠炎的免疫影响.上海铁道医学院学报,1995,9(4)219-222
62.周玲玲,方泰惠,杨舜民,等,复方苦参胶囊对大鼠免疫性结肠炎的保护作用.陕西中医,2004,25(1)：89-91
63.石云琼,刘少平,针灸治疗对溃疡性结肠炎患者细胞因子的影响.湖北中医杂志,2006,28(2)：11-13
64.丁水平,丁水生,李涵志,算盘子对溃疡性结肠炎大鼠细胞因子的影响.医药导报,2002,21(2)：76-77
65.王新月,杨莉莉,王雪茜,顾立刚,田德禄,溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响.中国中西医结合消化杂志,2006,14(6)：351-354
66.郑红斌,胡鸿毅,陆雄,等,清肠栓对溃疡性结肠炎防治作用的动物实验研究.上海中医药大学学报,2000,14(4)：54-56
67.高文艳,王长洪,林一帆,等,化瘀通络汤对大鼠实验性溃疡性结肠炎血小板活化的影响.中国中西医结合消化杂志,2007，15(2)：81-84
68.赵复锦,张雄,余小平,等,通因通用法治疗溃疡性结肠炎的临床及实验研究.中国中西医结合消化杂志,2005,13(2)：85-87
69.朱炳喜,吕愈敏,叶嗣懋,丹参对大鼠乙酸性溃疡性结肠炎黏膜保护作用的研究.中国中西医结合脾胃杂志,2000,8(4)：214-245
70.郑舜华,崔儒涛,补肺益肠方治疗溃疡性结肠炎的实验研究.上海中医药杂志,2000,(6)：10-12
71.江学良,权启镇,王东,等,鱼腥草治疗溃疡性结肠炎大鼠对结肠压力的影响.世界华人消化杂志,1999,7(7)：639
72.陈治水,危北海,张万岱,李道本,溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005,13(2)：133-136
1. Hanauer SB, Inflammatory bowel disease. In:Bennett JC, Plum F (eds.). Cecil Textbook of Medicine.20th ed Philadelphia:W. B.Saunders Company,1996, 707-715
2. Park SH, Kim YM, Yang SK, Kim SH, Byeon JS,Myung SJ, Cho YK, YuCS, Choi KS, Chung JW, Kim B, Choi KD, Kim JH. Clinical features andnatural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007,13:278-283
3. Br andt LJ, Bo l e y S J, Mi t sudo S, Clinical characteristics and natural history of colitis in theelderly. Am J Gastroenterol,1982,77:382-386
4. Lakatos PL, Recent trends in the epidemiology of inflammatory bowel diseases:up or down? World JGastroenterol,2006,12:6102-6108
5. Lakatos L, Lakatos PL, Is the incidence andprevalence of inflammatory bowel diseasesincreasing in Eastern Europe? Postgrad Med J 2006,82:332-337
6. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J, Colorectal cancer prevention in ulcerative colitis:a case-controlstudy. Aliment Pharmacol Ther.2000,14:145-153
7. Ameho CK, Adje i AA,Harrison EK, et al, Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor a production in trinitrobenzene sulphonic acid induced col it is.Gut,1997, 41(4):487-493
8. Bach MA, Bach JF, The use of monoclonal anti-T cell antibodies to study T cell imbalance in human diseases. Clin Exp Immunol,1981,45:449-456
9. Bhan AK,Mizoguchi E, Smith RN, et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev,1999,169:195-207
10. Neurath MF,Immunotherapy of inflammatory bowel disease:current concepts and future perspectives. Arch Immunol Ther Exp (Warsz),2000,48:81-84
11. Inoue S, Mat sumo to T, IidaM, et al, Characterization of cytokine expression in. the rectal mucosa of ulcerative colitis:correlation with disease activity. Am Jgastroenterol,1999,94:2441-2446
12. Lijima H,Takahashi I, Kishi D, et al, J Exp Med,1999,190(5):607-615
13. Boirivant M,Rennert PD, J Exp Med,1999,189(8):1169-1180
14. Dohi T, Fujihashi K,Kiyono H, et al, Gatroenterology,2000,119(6):724-733
15. Niessner M, Volk BA, Altetred Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Inmmunol,1995Sep,101:428-435
16. Fuss J, Neurath M,Boirivant M,et al, Disparate CD4+ lamina propria(LP) lympokine secretion profiles in inflammatory bowel disase. Crohn's disease Lpcells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest incersed secretion of IL-5.J Immunol,1996, 157:1261-1270.
17. Biuruvabt M, et al, J Exp Med,1998,188 (10):1929-1939
18.Macdlonald.TT, Gut,1998,42 (4):460-461
19. Schreiber S, Experimental immunomodulatory therapy of inflammatorybowel disease. Netherl J Med 1998,53:24-31
20.李琪佳,徐敏,宫恩聪,细胞因子与溃疡性结肠炎.中国煤炭工业医学杂志2001,4：411-413
21.Ferretti M, Neutralization of endogenous IL-lreceptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.J Clin Invest,1994,94:449-453
22.朱峰,钱家鸣,潘国宗,等,白细胞介素1β和白细胞介素8在实验性结肠炎发病中的作用及白细胞介素1受体拮抗剂治疗作用的探讨.中国医学科学院学报,1998,20：388-394
23. Cominelli F,Kam L,Casini-Raggi V,et al, Specific mucosal imbalance of IL-1 and IL-1 receptor antagonit (IL-lra). in IBD:A potential mechanism of chronic infammation. Gastroenterol,1994,106:A667
24..Isaacs KL, Sartor RB, Haskill S, et al, Cytokine messenger RNA profiles in inflammatory bowel disease muosa detected by polymerase chain reaction amplification. Gastroenterol,103:1587-1595,1992
25丁伟群,林庚金,徐三荣,钱立平,溃疡性结肠炎发病中白介素水平的变化.复旦学报2001,7：330-335
26 Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET,Strom TB, Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic of IL-1, IL-6 and TNF-g. J Immunol,1991,146:3523-3527
27 Willems J, Joniau M, Cinque S, van Damme J, Human granulocytechemotactic peptide (IL-8) as a specific neutrophildegranulator:comparison with other monokines. Immunology,1989,67:540-542
28 Mazzucchelli L, Hauser C, Zgraggen K, Wagner H, Hess M,Laissae JA, Mueller C, Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol,1994,144:997-1007
29. Kullberg MC, Ward JM,Gorelick PL,et al, Helicobacter hepatieus Triggers Colitis in Specific-Pathogen-Free Interleukin-10(IL-10)-Deficent Mice through an IL-2 and Gamma Interferon-Dependent Mechanism.Infect Immunol,1998,66:5157-5166
30. Schreiber S,Heinig T,Panzer U,et al, Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology,1995,108:21-23
31. Mullin GE, Vezza FR, Sampat A,et al, Abnormal IL-10 mRNA production in the intestinal mucosal lesions of inflammatory bowel disease. Gastroenterology 1993,104(3),182-188
32. Schreibei S, Heining T, HeiningT, et al, Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology,1995 Jan,108(1):35-66
33 Nielsen OH, Koppen T, Rudiger N, Horn Y, Eriksen J, KirmanL, Involvement of interleukin-4 and 10 in inflammatory boweldisease. Dig Dis Sci,1996,41:1786-1793
34 Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahonR, Whorwell PJ, Sinnott PJ, Hutchinson IV, Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigen,1999,54:386-390
35 Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, ParsonsHG, Madsen KL, Inhibition of poly (ADP-ribose) polymeraseattenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol,2000,279:641-651
36. Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A, Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line:role of the microtubule cytoskeleton. Free Radic Biol Med,2000,28:727-38
37. Oudkerk P, Bouma G,Visser T T, et al, Serumnitrate level in ulcerative colliti and Crohrs disease. Scand J Gastroenterol,1995,30:784-788
38. Grisham MB, Oxidants and free radicals in inflammatory bowel disease. Lancet, 1994,344:859-861
39. Collins CE, Cahill MR, Newland AC, Rampton DS, Platelets circulate in an actived state in inflammatory bowel disease. Gastroenter.ology,1994,106 (4):840-845 40. Nielsen OH,Brynskov J, Vainer B, Dig Dis. Sci,1996,41 (9):1780-1785
41. Koizumi M,King N, Lobb R,et al, Gastroenterology,1992,103 (3):840-847
42. Schumann GM.Bishop AE,Facer P,et al, Gut,1995,36 (7):411-418
43. 费保莹,细胞粘附分子与炎症性肠病.国外医学消化系统疾病分册,1999；19(1)： 15-17
44. Simmonds NJ, AllenRE, Stevens TRJ, et al, Chemilum inescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology,1992, 103:186-192
45. SedghiS, KeshavarzianA, KlamutM, et al, Elevated breath ethane levels inactive ulcerative colitis:Evidence for. excessive lipid peroxdation. Am J Gastroenterol, 1994,89:2217-2221
46.Tannahill CL, Stevenot SA, Campbell-Thompson M, e tal, Induction and immunolocalization of manganese super oxide dismutase in acute acetic acid-induced colitis in the rat. Gastroenterology,1995,109:800-805
47. Mulder TPJ, Verspaget HW, Janssens AR, et a, Decreases in two ntestinal. Cu/Zn containing proteins with an-tioxidant function in inflammatory bowel disease.Gut,1991,32:1146-1150
48. Ueyama H,et al, Gut,1998,43(1):48-55
49. Maciejewski J, Selleri C, Sato T, et al, Br J Haematol,1995/91:245-252
50.Anel A, Buferne M Boyer C, et al, Eur J Immunol,1.994,24(10):2469-2476
51. Callera F, Garcia AB, Falcai RP, et al, Br J Haematol,1998,100:698-703
52.吴国新,阮长耿, 血小板颗粒膜蛋白研究进展.中华血液杂志,1994,15(3)：162
53.江学良, 溃疡性结肠炎患者血小板活化的检测.新消化病杂志,1997,11(5)：736
54. Collins CE, Cihill MR, Newland AC,et al, Platelets circulation in anactivated state in inflammatory bowel disease. Gastroenterology,1994,106(4):840-845
55.徐萍,吴锡琛,血小板功能障碍：炎症性肠病研究的一种新动向.国外医学消化系统疾病分册,1996,16(1)：43
56.Graef V. Baggenstoss AH, Sauer WG, et al, Venous thromblsis occurring in nonspecific ulcerative colitis. Arch Intern Med,1996,117(3):337
57.张连峰,田曙光,王国新,溃疡性结肠炎患者血小板功能状态的研究.中国实用内科杂志,2000,20(2)：98-99
58. Sedghi S, Fields JZ, Klamut M, et al, Increased production of luminal enhanced chem. Hum in escence by the inflamed colonic mucosa in patients with ulcerative colitis.Gut,1993,34:1191-1195
59, Kerr 1F, Wyllle AH, Cntrie AR, Apoptosis:a basic biological phenomenon.with wikl ranging implications in tissue kinctics. Br J C mtar,1972,26:239-245
60. IwamotoM, Koji T,Makiyama K, Kohyski N, Nakane PK, Apoptosis of crypt Epithelial cell in ulcerative colitis. J Pathol 1996,180:152-159
61严瑾,欧阳钦,陈代云,等,溃疡性结肠炎中Fas/FasL介导的结肠上皮细胞凋亡.中华消化杂志,2001,21：397-399.
62张文俊,李兆申,许国铭,等,细胞调亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达的研究.中华消化内镜杂志,2003,20：262-264
63祝斌,李巧勤,陈垦,等,溃疡性结肠炎患者PMM凋亡与细胞因子水平及Bcl-2基因表达的关系.中国肛肠病杂志,2004,24：3-6.
64江学良,权启镇,孙自勤,王要军,齐风,王东,张修礼,‘溃疡性结肠炎患者淋巴细胞凋亡调控蛋白的表达.世界华人消化杂志,1999,7：902-905
65 Neurath M F, Finotto S, FussI, Boirivant M, Galls PR, Strober'W, Regulation of T-cell apoptosis in inflammatory bowel disease:to d ie or not to die, that is the mucosal question. Trends Immunoi 2001,22:21-26
66. Orholm M,Binder V, Sorensen TI, Rasmussen LP, Kyvik KO, Concordance of inflammatory bowel disease among Danish twins:results of a nationwide study. Sand J Gastroenterol,2000,35:1075-1081
67. Orchard TR,Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000,118:274-278
68. Einerhand AW, Renes IB, Makkink MK, Van Der Sluts M Buller HA, Dekker J. Role of mucins in inflammatory bowel disease:important lessons from experimental models. Eur J Gastroenterol Hepatml,2002,14:757-765
69. Birrenbach T, Bocker U, Inflammatory boweldisease and smoking:a review of epidemiology,pathophysiology, and therapeutic implications. Inflamm Bowel Dis,2004, 10:848-859
70. Cosnes J, Tobacco and IBD:relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol,2004,18:481-496
71. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS, Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol,1988,23: 1147-1152
72. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR, Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis, 2007,13:108-115
73. Scott DA, Martin M, Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J Gastroenterol,2006, 12:7451-7459
74. Ingram JR, Rhodes J, Evans BK, Thomas GA, Preliminary observations of oral nicotine therapy for inflammatory bowel disease:an open-label phase Ⅰ-Ⅱ study of tolerance. Inflamm Bowel Dis,2005,11:1092-1096
75. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J, Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy:a pilot study. Aliment Pharmacol Ther,1997,11:663-671
76 Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD, Transdermal nicotine for mildly to moderately active ulcerative colitis. Arandomized, double-blind, placebo-controlled trial. Ann Intern Med,1997,126:364-371
77 Jantchou P, Monnet E, Carbonnel F, Environmental risk factors in Crohn's disease and ulcerative colitis (excluding tobacco and appendicectomy). Gastroenterol Clin Biol,2006,30:859-867
78 Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA, Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005,22:309-315
79 Godet PG, May GR, Suther land LR, Metaanalysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995,37:668-673.
80. Mayer EA, The neurobiology of stress andgastrointestinal disease. Gut,2000, 47:861-8698
81. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, KeM, Tache Y, Wood JD. Fundamentals of neurogastroenterology:basic science. Gastroenterology,2006,130:1391-1411
82 Heinrichs SC, Tache Y, Therapeutic potential ofCRF receptor antagonists:a. gut-brain perspective.Expert Opin Investig Drugs,2001,10:647-659
83. Glavin GB, Murison R, Overmier JB, Pare WP,Bakke HK, HenkePG, Hernandez DE, The neurobiology of stress ulcers. Brain Res Brain Res Rev,1991,16:301-343
84. Madara JL, Podolsky DK, King NW, Sehgal PK, Moore R, Winter HS, Characterization of spontaneous colitis in cottontoptamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology,1985,88(1 Pt 1):13-19
85. Theis MK, Boyko EJ, Patient perceptions of causes of inflammatory bowel disease. Ain J G astroenterol,1994,89:1920
86.Mayer EA, The neurobiology of stress and gastrointestinal disease. Gut,2000, 47:861-869
87.] Qiu BS, Valiance BA, Blennerhassett PA, Collins SM, The role of CD4+lymphocytes in the susceptibility of mice to stress induced
88. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, Gonzalez-Huix F, Rier.a J, Gonzalez-Lara V, Dominguez-Abascal F, Gine JJ,Moles J, Gomollon F, Gassull MA, Randomizedclinical trial of Plantago ovata seeds (dietary fiber)as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol,1999,94:427-433
89. Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH, Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr, J 2005,4:7
90. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR, Influence of dietary factors on the clinical course of ulcerative colitis:a prospective cohort study. Gut,2004,53:1479-1484
91 Tilg H, Kaser A, Diet and relapsing ulcerative colitis:take off the meat? Gut, 2004,53:1399-1401
92 Winawer SJ, Screening of colorectal cancer. Surg Oncol Clin N Am,2005,14:699-722
93 Russel MG, Engels LG, Muris JW, Limonard CB, Volovics A, Brummer RJ, Stockbrugger RW, Modern life'in the epidemiology of inflammatory bowel disease:a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol, 1998,10:243-249
94 Guarner F, Microecology as a target for therapeutic intervention in inflammatory bowel disease. Idrugs,2003,6:868-873
95 Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H, Mucosal flora in inflammatory bowel disease. Gastroenterology,2002,122:44-54
96 Katz JA, Itoh J, Fiocchi C, Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol,1999,15:291-297
97.董军梅,魏琴,柳氮磺吡啶保留灌肠加电磁波治疗溃疡性结肠炎. 中国中医药现代远程教育,2008,6：784
98.吴小珑,陈健芳,柳氮磺胺吡啶等保留灌肠治疗溃疡性结肠炎.基层医学论坛,2006,10： 719-720
99. 严明确,白学松,任文涛,溃疡性结肠炎药物治疗的现状. 现代医药卫生,2006,22： 2817-2818
100. 宋卫生,刘思德,溃疡性结肠炎药物治疗进展.中国消化内镜,2008,2：18-20
101. Jarnerot G, Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology,2006,130:286, author reply 287
102. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ,Present D, Sands BE, Colombel JF, Infliximabfor induct ion and maintenance therapy for ulcerative colitis. N Engl J Med,2005,353:2462-2476
103.何相宜, 陈维雄,英昔单抗治疗中至重度溃疡性结肠炎的研究进展. 国际消化病杂志,2007,27：169-171
104钱家鸣,路新卿,肿瘤坏死因子拮抗剂治疗炎症性肠病. 中国实用内科杂志,2007,27： 1442-1444
105夏冰,程虹,溃疡性结肠炎的生物治疗. 临床消化病杂志,2007,19：1-19
106杨景勋,Infliximab不良反应.药物不良反应杂志,2001,3：176-178
107张道权,吴正祥,炎症性肠病的抗肿瘤坏死因子治疗安全评价. 临床荟萃,2007,22： 145-147
108 Lees CW, Ali A, Thompson AI, Ho GT, ForsytheRO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR,Wilson DC, Arnott ID, Satsangi J, The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice:analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2008 N.ov 4. [Epub ahead of print]
109 Shah SB, Hanauer SB, Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord,2008,8:159-168
110陈尉华,陆伦根,炎症性肠病生物制剂治疗的研究进展.胃肠病学,2007,12：252-254
111庞智,郑家驹,炎症性肠病生物学治疗的研究进展. 中国处方药,2007,6：39-41
112何影,欧阳钦,生长因子治疗炎症性肠病.国际消化病杂志,2007,27：164-166
1.中华医学会消化病学分会炎症性肠病协作组,对我国炎症性肠肠病诊断治疗规范的共识意见.胃肠病学,2007,12(8)：488-494
2.贾黎明,周春立,炎症性肠病的内镜检查.炎症性肠病基础与临床.北京：科学出版社,2001,195
3.施先艳,邓长生.溃疡性结肠炎.炎症性肠病。北京：人民卫生出版社,1998,183
4. Rachmilewitz D, On behalf of an International Study Group. Coated mesalazine (5-aminosallicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis:a randomised trial. Br Med J,1989,298:82-86
5.陈治水,危北海,张万岱,李道本,溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005,13(2)：133-136